ReleVote

Countering CCP Act

Bill Number
S. 4939
Origin Chamber
Senate
Congress
119th Congress, Session 2
Status
Introduced
Latest Action
2026-06-24: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Last Updated
2026-07-07T05:08:21Z

AI-Generated Summary

Summary of S. 4939: Countering Chinese Cyberthreats for Patients Act (Countering CCP Act)

Purpose

This legislation directs the Secretary of Health and Human Services, through the Food and Drug Administration (FDA), to examine certain medical devices made in the People's Republic of China for cybersecurity risks. It aims to protect patient data and device security by allowing recalls where risks are found or required information is not provided.

Key Provisions

Significant Changes to Existing Law

This bill adds new authority for the FDA to conduct origin-specific cybersecurity reviews and issue recalls for medical devices, expanding beyond standard FDA oversight under the Federal Food, Drug, and Cosmetic Act. It introduces requirements tied to manufacturer location or control by China, which do not exist in current device regulation for cybersecurity.

Potential Impacts

Main Stakeholders Affected

Notable Legal, Constitutional, or Political Implications

The bill raises questions about due process for manufacturers facing recalls without prior hearings and potential challenges under international trade agreements. It highlights national security priorities in healthcare technology but could face legal scrutiny regarding selective enforcement based on foreign origin.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Sen. Cotton, Tom [R-AR]

Recent Actions

Bill Versions